XML 84 R73.htm IDEA: XBRL DOCUMENT
v3.25.1

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2025 | Mar. 31, 2024
Segment Reporting Information [Line Items] |  |
Sales | $ 15,529 | $ 15,775
Increase in hedge revenue | 58 | 54
Revenue related to the sale of the marketing rights | 95 | 61
U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 8,522 | 7,478
Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,007 | 8,297
Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 15,226 | 15,517
Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 8,429 | 7,410
Operating Segments | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,797 | 8,107
Corporate, Non-Segment |  |
Segment Reporting Information [Line Items] |  |
Sales | 303 | 258
Corporate, Non-Segment | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 93 | 68
Corporate, Non-Segment | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 210 | 190
Pharmaceutical | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 13,638 | 14,006
Pharmaceutical | Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,927 | 6,936
Pharmaceutical | Operating Segments | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 5,711 | 7,070
Pharmaceutical | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,205 | 6,947
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 4,308 | 4,119
Pharmaceutical | Operating Segments | Keytruda | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 2,897 | 2,828
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |
Segment Reporting Information [Line Items] |  |
Sales | 312 | 292
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 145 | 135
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 168 | 157
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |
Segment Reporting Information [Line Items] |  |
Sales | 258 | 255
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 186 | 173
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 72 | 82
Pharmaceutical | Operating Segments | Welireg |  |
Segment Reporting Information [Line Items] |  |
Sales | 137 | 85
Pharmaceutical | Operating Segments | Welireg | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 123 | 77
Pharmaceutical | Operating Segments | Welireg | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 15 | 7
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |
Segment Reporting Information [Line Items] |  |
Sales | 119 | 71
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 101 | 58
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 18 | 12
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,327 | 2,249
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 536 | 488
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 790 | 1,761
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 539 | 570
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 423 | 438
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 116 | 133
Pharmaceutical | Operating Segments | Vaxneuvance |  |
Segment Reporting Information [Line Items] |  |
Sales | 230 | 219
Pharmaceutical | Operating Segments | Vaxneuvance | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 139 | 161
Pharmaceutical | Operating Segments | Vaxneuvance | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 92 | 58
Pharmaceutical | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 228 | 216
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 164 | 149
Pharmaceutical | Operating Segments | RotaTeq | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 64 | 67
Pharmaceutical | Operating Segments | Capvaxive |  |
Segment Reporting Information [Line Items] |  |
Sales | 107 | 0
Pharmaceutical | Operating Segments | Capvaxive | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 106 | 0
Pharmaceutical | Operating Segments | Capvaxive | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 1 | 0
Pharmaceutical | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 41 | 61
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | (2) | 6
Pharmaceutical | Operating Segments | Pneumovax 23 | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 42 | 55
Pharmaceutical | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 441 | 440
Pharmaceutical | Operating Segments | Bridion | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 378 | 329
Pharmaceutical | Operating Segments | Bridion | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 63 | 111
Pharmaceutical | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 208 | 174
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 102 | 74
Pharmaceutical | Operating Segments | Prevymis | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 106 | 100
Pharmaceutical | Operating Segments | Dificid |  |
Segment Reporting Information [Line Items] |  |
Sales | 83 | 73
Pharmaceutical | Operating Segments | Dificid | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 72 | 68
Pharmaceutical | Operating Segments | Dificid | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 11 | 5
Pharmaceutical | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | 70 | 56
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 42 | 33
Pharmaceutical | Operating Segments | Zerbaxa | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 28 | 23
Pharmaceutical | Operating Segments | Winrevair |  |
Segment Reporting Information [Line Items] |  |
Sales | 280 | 0
Pharmaceutical | Operating Segments | Winrevair | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 268 | 0
Pharmaceutical | Operating Segments | Winrevair | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 12 | 0
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |
Segment Reporting Information [Line Items] |  |
Sales | 106 | 98
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 97 | 90
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 9 | 8
Pharmaceutical | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 68 | 70
Pharmaceutical | Operating Segments | Adempas | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 68 | 70
Pharmaceutical | Operating Segments | Lagevrio |  |
Segment Reporting Information [Line Items] |  |
Sales | 102 | 350
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 35 | 45
Pharmaceutical | Operating Segments | Lagevrio | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 67 | 305
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 90 | 111
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 51 | 50
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 39 | 61
Pharmaceutical | Operating Segments | Delstrigo |  |
Segment Reporting Information [Line Items] |  |
Sales | 67 | 56
Pharmaceutical | Operating Segments | Delstrigo | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 15 | 12
Pharmaceutical | Operating Segments | Delstrigo | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 44
Pharmaceutical | Operating Segments | Pifeltro |  |
Segment Reporting Information [Line Items] |  |
Sales | 45 | 42
Pharmaceutical | Operating Segments | Pifeltro | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 32 | 29
Pharmaceutical | Operating Segments | Pifeltro | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 13 | 13
Pharmaceutical | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 50 | 46
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 13 | 15
Pharmaceutical | Operating Segments | Belsomra | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 37 | 32
Pharmaceutical | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 184
Pharmaceutical | Operating Segments | Simponi | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 184
Pharmaceutical | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 39
Pharmaceutical | Operating Segments | Remicade | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 39
Pharmaceutical | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 549 | 419
Pharmaceutical | Operating Segments | Januvia | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 344 | 183
Pharmaceutical | Operating Segments | Januvia | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 204 | 236
Pharmaceutical | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 247 | 251
Pharmaceutical | Operating Segments | Janumet | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 65 | 39
Pharmaceutical | Operating Segments | Janumet | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 182 | 212
Pharmaceutical | Operating Segments | Other pharmaceutical |  |
Segment Reporting Information [Line Items] |  |
Sales | 729 | 632
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 184 | 165
Pharmaceutical | Operating Segments | Other pharmaceutical | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 545 | 467
Animal Health | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,588 | 1,511
Animal Health | Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 502 | 474
Animal Health | Operating Segments | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,086 | 1,037
Animal Health | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 924 | 850
Animal Health | Operating Segments | Livestock | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 194 | 166
Animal Health | Operating Segments | Livestock | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | 730 | 683
Animal Health | Operating Segments | Companion Animal |  |
Segment Reporting Information [Line Items] |  |
Sales | 664 | 661
Animal Health | Operating Segments | Companion Animal | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 308 | 308
Animal Health | Operating Segments | Companion Animal | Non-US |  |
Segment Reporting Information [Line Items] |  |
Sales | $ 356 | $ 354

X
- Definition Increase (Decrease) In Hedge Revenue + References No definition available. + Details
Name: | mrk_IncreaseDecreaseInHedgeRevenue
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WeliregMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaxneuvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CapvaxiveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WinrevairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DelstrigoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PifeltroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |